MedImmune files intranasal flu vaccine in EU
This article was originally published in Scrip
Executive Summary
MedImmune, the global biologics unit of AstraZeneca, has submitted a marketing authorisation application for its intranasal live attenuated influenza vaccine (LAIV) to the EMEA.